Heron Therapeutics Inc (NASDAQ:HRTX) Expected to Post Quarterly Sales of $33.63 Million

Wall Street brokerages predict that Heron Therapeutics Inc (NASDAQ:HRTX) will announce $33.63 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Heron Therapeutics’ earnings. The highest sales estimate is $37.20 million and the lowest is $30.00 million. Heron Therapeutics posted sales of $19.79 million in the same quarter last year, which suggests a positive year-over-year growth rate of 69.9%. The firm is scheduled to report its next earnings report on Wednesday, November 6th.

According to Zacks, analysts expect that Heron Therapeutics will report full-year sales of $130.42 million for the current fiscal year, with estimates ranging from $124.00 million to $139.30 million. For the next year, analysts anticipate that the firm will report sales of $197.38 million, with estimates ranging from $150.00 million to $253.70 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.02. Heron Therapeutics had a negative return on equity of 56.89% and a negative net margin of 172.07%. The firm had revenue of $36.66 million during the quarter, compared to the consensus estimate of $31.04 million.

Several brokerages have recently weighed in on HRTX. Evercore ISI reaffirmed a “buy” rating and issued a $75.00 target price on shares of Heron Therapeutics in a research report on Tuesday, August 13th. ValuEngine raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. BidaskClub raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 10th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $38.00 target price on shares of Heron Therapeutics in a research report on Monday, August 5th. Finally, Cowen reaffirmed a “buy” rating on shares of Heron Therapeutics in a research report on Thursday, May 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. Heron Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $52.67.

Large investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new position in shares of Heron Therapeutics in the fourth quarter worth about $13,679,000. Boston Advisors LLC lifted its stake in shares of Heron Therapeutics by 443.9% in the first quarter. Boston Advisors LLC now owns 134,559 shares of the biotechnology company’s stock worth $3,288,000 after acquiring an additional 109,819 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Heron Therapeutics by 6.5% in the fourth quarter. Legal & General Group Plc now owns 27,564 shares of the biotechnology company’s stock worth $716,000 after acquiring an additional 1,679 shares in the last quarter. Virginia Retirement Systems ET AL lifted its stake in shares of Heron Therapeutics by 2.3% in the first quarter. Virginia Retirement Systems ET AL now owns 36,100 shares of the biotechnology company’s stock worth $882,000 after acquiring an additional 800 shares in the last quarter. Finally, Pier Capital LLC lifted its stake in shares of Heron Therapeutics by 6.3% in the first quarter. Pier Capital LLC now owns 269,514 shares of the biotechnology company’s stock worth $6,587,000 after acquiring an additional 15,914 shares in the last quarter.

Shares of NASDAQ HRTX traded down $0.71 on Friday, hitting $17.38. The company had a trading volume of 441,401 shares, compared to its average volume of 861,797. Heron Therapeutics has a 12-month low of $15.68 and a 12-month high of $41.10. The business has a 50 day moving average of $17.86 and a two-hundred day moving average of $21.15. The company has a quick ratio of 3.70, a current ratio of 4.01 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.44 billion, a P/E ratio of -7.12 and a beta of 1.49.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Article: What is Green Investing?

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.